PT - JOURNAL ARTICLE AU - Nguyen, Long H. AU - Joshi, Amit D. AU - Drew, David A. AU - Merino, Jordi AU - Ma, Wenjie AU - Lo, Chun-Han AU - Kwon, Sohee AU - Wang, Kai AU - Graham, Mark S. AU - Polidori, Lorenzo AU - Menni, Cristina AU - Sudre, Carole H. AU - Anyane-Yeboa, Adjoa AU - Astley, Christina M. AU - Warner, Erica T. AU - Hu, Christina Y. AU - Selvachandran, Somesh AU - Davies, Richard AU - Nash, Denis AU - Franks, Paul W. AU - Wolf, Jonathan AU - Ourselin, Sebastien AU - Steves, Claire J. AU - Spector, Tim D. AU - Chan, Andrew T. AU - , TI - Racial and ethnic differences in COVID-19 vaccine hesitancy and uptake AID - 10.1101/2021.02.25.21252402 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.25.21252402 4099 - http://medrxiv.org/content/early/2021/02/28/2021.02.25.21252402.short 4100 - http://medrxiv.org/content/early/2021/02/28/2021.02.25.21252402.full AB - Background Racial and ethnic minorities have been disproportionately impacted by COVID-19. In the initial phase of population-based vaccination in the United States (U.S.) and United Kingdom (U.K.), vaccine hesitancy and limited access may result in disparities in uptake.Methods We performed a cohort study among U.S. and U.K. participants in the smartphone-based COVID Symptom Study (March 24, 2020-February 16, 2021). We used logistic regression to estimate odds ratios (ORs) of COVID-19 vaccine hesitancy (unsure/not willing) and receipt.Results In the U.S. (n=87,388), compared to White non-Hispanic participants, the multivariable ORs of vaccine hesitancy were 3.15 (95% CI: 2.86 to 3.47) for Black participants, 1.42 (1.28 to 1.58) for Hispanic participants, 1.34 (1.18 to 1.52) for Asian participants, and 2.02 (1.70 to 2.39) for participants reporting more than one race/other. In the U.K. (n=1,254,294), racial and ethnic minorities had similarly elevated hesitancy: compared to White participants, their corresponding ORs were 2.84 (95% CI: 2.69 to 2.99) for Black participants, 1.66 (1.57 to 1.76) for South Asian participants, 1.84 (1.70 to 1.98) for Middle East/East Asian participants, and 1.48 (1.39 to 1.57) for participants reporting more than one race/other. Among U.S. participants, the OR of vaccine receipt was 0.71 (0.64 to 0.79) for Black participants, a disparity that persisted among individuals who specifically endorsed a willingness to obtain a vaccine. In contrast, disparities in uptake were not observed in the U.K.Conclusions COVID-19 vaccine hesitancy was greater among racial and ethnic minorities, and Black participants living in the U.S. were less likely to receive a vaccine than White participants. Lower uptake among Black participants in the U.S. during the initial vaccine rollout is attributable to both hesitancy and disparities in access.Competing Interest StatementLP, CH, SS, RD, and JW are employees of Zoe Global Ltd. TDS is a consultant to Zoe Global Ltd. DAD and ATC previously served as investigators on a clinical trial of diet and lifestyle using a separate smartphone application that was supported by Zoe Global Ltd.Funding StatementZoe provided in kind support for all aspects of building, running and supporting the app and service to users worldwide. LHN is supported by the NIH/NIDDK NIH K23DK125838, American Gastroenterological Association Research Scholars Award, and Crohn's and Colitis Foundation Career Development Award and Research Fellowship Award. DAD is supported by the NIH/NIDDK K01DK120742. LHN and DAD are supported by the American Gastroenterological Association-Takeda COVID-19 Rapid Response Research Award (AGA2021-5102). The Massachusetts Consortium on Pathogen Readiness (MassCPR) and Mark and Lisa Schwartz supported MGH investigators. CM is supported by the Chronic Disease Research Foundation. CM and TDS are supported by the Medical Research Council AimHy Project Grant. ATC is the Stuart and Suzanne Steele MGH Research Scholar and Stand Up to Cancer scientist. Sponsors had no role in study design, analysis, and interpretation of data, report writing, and the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research study was approved by the Mass General Brigham Human Research Committee (Institutional Review Board Protocol 2020P000909) and King's College London Ethics Committee (REMAS ID 18210).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData collected using the COVID Symptom Study smartphone application are being shared with other health researchers through the U.K. National Health Service-funded Health Data Research UK (HDRUK) and Secure Anonymised Information Linkage consortium, housed in the U.K. Secure Research Platform (Swansea, UK). Anonymized data are available to be shared with researchers according to their protocols in the public interest. U.S. investigators are encouraged to coordinate data requests through the Coronavirus Pandemic Epidemiology (COPE) Consortium.